The market for organs-on-chips (OOCs), the cell culture chips that imitate the activities, mechanisms and responses of body organs, will be worth $284 million by 2022, according to interviews with industry leaders from The Business Research Company (TBRC) in its report Organ-On-Chip (OOC) Global Opportunities And Strategies To 2022. The microarray market’s growth is expected to accelerate going forward. The organ on a chip market is still in the development phase but some commercialized products have established markets. The lung on a chip market is currently the largest segment, followed by the heart on a chip market, the liver-on-chip market, the intestine-on-chip market, the kidney-on-chip market, the skin-on-chip market, and the blood-brain barrier-on-chip market.
Organs-on-chips are microfluidic 3D cell culture devices that closely mimic the key physiological functions of body organs. The chips are not designed to biomimic an entire organ, but simulate the physiology of a single functional unit of an organ system. They have resulted from scientific advances in cell biology, microfabrication and microfluidics which allow the emulation of the human micro environment in vitro. This unique feature of organ on chips is made possible by integrating biology with advanced engineering technologies. Human organs-on-chips (OOCs) are miniaturized versions of lungs, livers, kidneys, heart, brain, intestines and other vital human organs embedded in a chip.
Download a sample of the report at https://www.thebusinessresearchcompany.com/sample.aspx?id=805&type=smp
North America, particularly the USA, is the largest market for organs-on-chips, followed by Europe. These are the regions where most drug development is currently undertaken. However, Asia and the rest of the world will also see significant growth in the market up to 2021.
Since the lab-on-a-chip market is still in the research and development phase, and has not been completely commercialized, it is dependent on government grants. For example, in 2012 the USA’s National Institutes of Health (NIH) established a ‘Tissue Chip for Drug Screening’ initiative. The establishment of this program was aided by NIH’s Common Fund and the National Institute of Neurological Disorders and Stroke. NIH plans to commit up to $70 million over five years for the program. In total, 15 NIH institutes and centers are assisting in the coordination of this program. Seventeen research projects were awarded about $13 million in July 2012. In 2014, NIH began the second phase of funding for the Tissue Chip for Drug Screening Program in which 11 institutes were supported by $17 million. In September 2017, NIH funded 13 institutions. The funds allocated were close to $15 million.
The players in the organs on chips market are primarily university spinoffs involved in the commercialization of OOC prototypes developed in the universities. These business arms include CN-Bio Innovations, InSphero, Mimetas, TissUse, Hµrel and Nortis.
Download Complete Table of Contents at https://www.thebusinessresearchcompany.com/sample.aspx?id=805&type=toc
About The Business Research Company
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info